Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
15
TMCI Quote, Financials, Valuation and Earnings
Last price:
$2.75
Seasonality move
:
14.54%
Day range:
$2.63 - $2.78
52-week range:
$2.56 - $10.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.79x
P/B ratio:
1.96x
Volume:
613.8K
Avg. volume:
943.7K
1-year change:
-64.65%
Market cap:
$174.6M
Revenue:
$209.4M
EPS (TTM):
-$0.79
Analysts' Opinion
-
Consensus RatingTreace Medical Concepts, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.56, Treace Medical Concepts, Inc. has an estimated upside of 99.64% from its current price of $2.74.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $2.74.
Fair Value
-
According to the consensus of 5 analysts, Treace Medical Concepts, Inc. has 99.64% upside to fair value with a price target of $6.56 per share.
TMCI vs. S&P 500
-
Over the past 5 trading days, Treace Medical Concepts, Inc. has underperformed the S&P 500 by -8.34% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Treace Medical Concepts, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Treace Medical Concepts, Inc. has grown year-over-year revenues for 21 quarters straight. In the most recent quarter Treace Medical Concepts, Inc. reported revenues of $50.2M.
Earnings Growth
-
Treace Medical Concepts, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Treace Medical Concepts, Inc. reported earnings per share of -$0.26.
Enterprise value:
187.5M
EV / Invested capital:
--
Price / LTM sales:
0.79x
EV / EBIT:
--
EV / Revenue:
0.86x
PEG ratio (5yr expected):
-0.73x
EV / Free cash flow:
-7.12x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$174.8M
Return On Assets:
-24.12%
Net Income Margin (TTM):
-22.89%
Return On Equity:
-49.13%
Return On Invested Capital:
-29.15%
Operating Margin:
-31.22%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $174.7M | $202.9M | $218.9M | $45.1M | $50.2M | |
| Gross Profit | $141.2M | $163.5M | $174.8M | $36.1M | $39.7M | |
| Operating Income | -$48.1M | -$62.3M | -$48.4M | -$15.1M | -$15.7M | |
| EBITDA | -$41.9M | -$54.3M | -$38.4M | -$13M | -$12.9M | |
| Diluted EPS | -$0.79 | -$0.99 | -$0.79 | -$0.25 | -$0.26 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $135.4M | $127.9M | $187.1M | $157.6M | $138M | |
| Total Assets | $137.6M | $156.4M | $240.4M | $212.9M | $196.6M | |
| Current Liabilities | $10.7M | $22.6M | $33.2M | $38.3M | $40.9M | |
| Total Liabilities | $40.2M | $94.2M | $102.5M | $108M | $107.4M | |
| Total Equity | $97.4M | $62.2M | $137.9M | $104.9M | $89.2M | |
| Total Debt | $29.3M | $71.7M | $69.3M | $69.7M | $66.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$40.5M | -$32.4M | -$12.2M | -$11.8M | -$9.1M | |
| Cash From Investing | -$150.3M | $37M | $7M | $5.8M | $8.7M | |
| Cash From Financing | $109.5M | $299K | $721K | $8K | -$10K | |
| Free Cash Flow | -$52M | -$43.2M | -$26.3M | -$14.7M | -$11.9M | |
TMCI
Sector
Market Cap
$174.6M
$28.5M
Price % of 52-Week High
25.39%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-0.15%
-1.33%
1-Year Price Total Return
-64.65%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.85
200-day SMA
Sell
Level
$6.44
Bollinger Bands (100)
Sell
Level
4.32 - 7.38
Chaikin Money Flow
Sell
Level
-11.3M
20-day SMA
Sell
Level
$3.02
Relative Strength Index (RSI14)
Sell
Level
23.91
ADX Line
Sell
Level
47.51
Williams %R
Neutral
Level
-69.012
50-day SMA
Sell
Level
$5.08
MACD (12, 26)
Sell
Level
-0.72
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-27.7M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.2633)
Sell
CA Score
(Annual)
Level (-1.0252)
Buy
Beneish M-Score
(Annual)
Level (-2.8019)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.6833)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. It offers Lapiplasty, a bunion surgery for three-dimensional bunion correction. It operates and distributes its products and services under the following trademarks: Treace Medical Concepts, Lapiplasty, Fast Grafter, Align My Toe, The Future of Hallux Valgus, Fix It Right The First Time, and Plantar Python. The company was founded by John T. Treace in July 2013 and is headquartered in Ponte Vedra Beach, FL.
Stock Forecast FAQ
In the current month, TMCI has received 2 Buy ratings 3 Hold ratings, and 0 Sell ratings. The TMCI average analyst price target in the past 3 months is $6.56.
-
Where Will Treace Medical Concepts, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Treace Medical Concepts, Inc. share price will rise to $6.56 per share over the next 12 months.
-
What Do Analysts Say About Treace Medical Concepts, Inc.?
Analysts are divided on their view about Treace Medical Concepts, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Treace Medical Concepts, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Treace Medical Concepts, Inc.'s Price Target?
The price target for Treace Medical Concepts, Inc. over the next 1-year time period is forecast to be $6.56 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is TMCI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Treace Medical Concepts, Inc. is a Hold. 3 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of TMCI?
You can purchase shares of Treace Medical Concepts, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Treace Medical Concepts, Inc. shares.
-
What Is The Treace Medical Concepts, Inc. Share Price Today?
Treace Medical Concepts, Inc. was last trading at $2.75 per share. This represents the most recent stock quote for Treace Medical Concepts, Inc.. Yesterday, Treace Medical Concepts, Inc. closed at $2.74 per share.
-
How To Buy Treace Medical Concepts, Inc. Stock Online?
In order to purchase Treace Medical Concepts, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TMCI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TMCI
Sector
P/E ratio
--
23.75x
PEG ratio
-0.73x
-0.01x
P/B ratio
1.96x
1.83x
Price / LTM sales
0.79x
1.60x
Growth Metrics
TMCI
Sector
Revenue growth
11.37%
4.85%
Earnings growth
-3.89%
11.11%
Revenue (5-year growth)
39.65%
6.45%
Earnings forecast
-$0.24
-$0.20
Profitability
TMCI
Sector
Profitability FY 2024
$168.3M
$3.6M
Return on invested capital
-29.15%
-30.98%
Return on assets
-24.12%
-27.62%
Return on equity
-49.13%
-36.69%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
TMCI
Sector
Total cash
$57.4M
$27.2M
Short term investments
$64.3M
$25.7M
Total assets
$217.1M
$79.7M
Long term debt
$66.5M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
